Quetiapine: Dose-response relationship in schizophrenia

CNS Drugs

Volumn 22, Issue 1, 2008, Pages 69-72

  Citrome, Leslie ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Antipsychotics, therapeutic use; Dose response; Quetiapine, therapeutic use; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL PRACTICE; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NOTE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 36949016637     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822010-00005     Document Type: Note

References (24)

1. Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs 2007; 22 (1): 49-68
2. Citrome L, Jaffe A, Levine J, et al. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 2005; 66 (12): 1512-6
3. Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 2005; 25 (4): 388-91
4. Citrome L, Jaffe A, Levine J. Datapoints: the ups and downs of dosing second-generation antipsychotics. Psychiatr Serv 2007; 58 (1): 11
5. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003; 12 (1): 41-8
6. Citrome L, Jaffe A, Levine J, et al. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr Serv 2002; 53 (10): 1212
7. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16 (2): 158-69
8. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96 (4): 265-73
9. Lieberman JA, McEvoy JP, Swartz MS, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353 (12): 1209-23
10. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163 (4): 611-22
11. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163 (4): 600-10
12. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007; 164 (3): 415-27
13. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164 (7): 1050-60
14. AstraZeneca. Seroquel (quetiapine fumarate) tablets: product information [online]. Available from URL: http://www.astrazeneca-us.com/pi/seroquel.pdf [Accessed 2007 Oct 10]
15. Boidi G, Ferro M. Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study. Hum Psychopharmacol 2007; 22 (5): 299-306
16. Pae CU, Kim JJ, Lee CU, et al. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. J Clin Psychiatry 2007; 68 (3): 399-405
17. Smith MA, McCoy R, Hamer-Maansson J, et al. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol 2005; 25 (4): 331-5
18. Hatim A, Habil H, Jesjeet SG, et al. Safety and efficacy of rapid dose administration of quetiapine in bipolar mania. Hum Psychopharmacol 2006; 21 (5): 313-8
19. Pae CU, Ghaemi SN, Kim TS, et al. Rapid titration versus conventional titration of quetiapine in the treatment of bipolar mania: a preliminary trial. Int Clin Psychopharmacol 2005; 20 (6): 327-30
20. Pajonk FG, Schwertner AK, Seelig MA. Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series. J Psychopharmacol 2006; 20 (1): 119-24
21. AstraZeneca. Seroquel XR (quetiapine fumarate) extended-release tablets: product information [online]. Available from URL: http://www.astrazeneca-us.com/ pi/seroquelxr.pdf [Accessed 2007 Oct 10]
22. Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68 (6): 832-42
23. AstraZeneca. Summary: a Canadian, multicentre, double-blind, randomized, parallel-group study of the safety, tolerability, and efficacy of treatment with higher doses of quetiapine fumarate (Seroquel) greater than 800 mg/day in schizophrenic or schizoaffective subjects [online]. Available from URL: http://www.astrazenecaclinicaltrials.com/Article/526327.aspx [Accessed 2007 Oct 10]
24. Lindenmayer JP, Citrome L. High dose of quetiapine in treating subjects with treatment refractory schizophrenia or schizoaffective disorder (NCT00297947) [online]. Available from URL: http://www.clinicaltrials.gov/ct/ show/NCT00297947 [Accessed 2007 Oct 10]